Dawna D Allore, RN, Elizabeth A. Koselke, PharmD, Shawna L Kraft, PharmD, BCOP, Emily R Mackler, PharmD, BCOP, Bernard L Marini, PharmD, Suzette C Walker, DNP, FNP-BC, AOCNP
There are numerous opportunities to improve quality in the prescribing and monitoring of patients receiving oral anticancer medications.
Emily R. Mackler, PharmD, BCOP, Oncology Clinical Pharmacist, Michigan Oncology Quality Consortium at the University of Michigan Comprehensive Cancer Center, and Adjunct Clinical Associate Professor at the University of Michigan College of Pharmacy, Ann Arbor, discusses the clinical significance of her study, “Implementation of and Satisfaction with an Outpatient Oral Anticancer Therapy Program.”
Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost
Oral chemotherapy utilization and availability have increased in the past several years. Of the new oncologic agents in development, 30% to 35% are oral preparations.1 With the increasing development of new oral anticancer therapies, there have also been growing concerns regarding adherence, toxicity, and cost.
Review this study that aims to quantify the use of oral anticancer agents and analyze the incidence of various drug-related problems among patients treated with these medications.
Fluorouracil Overdose: Clinical Manifestations and Comprehensive Management During and After Hospitalization
Ivyruth W Andreica, BSN, PharmD, Taylor Ortiz, MD, Erin Pfeifer, PharmD, BCPS, Marina Rozov, PharmD, BCPS, Anastasiya Shakurova, PharmD, Erica Tavares, PharmD, BCPS
Trace the overall management of a fluorouracil overdose from initial exposure, through hospitalization and posthospitalization, to recovery.
Pharmacist-Run Vaccination and Medication Management Service for Patients After Bone Marrow Transplant
With advances in technique and supportive care, bone marrow transplant (BMT) patients have a longer life expectancy now than when BMT was first performed more than 40 years ago. Despite much higher mortality rates than the general population, up to 80% of BMT patients who survive 5 years posttransplantation will be alive 20 years posttransplantation. However, patients who live longer can be at higher risk for complications, in part because of changes in their body’s immune system. One of these concerns is the loss of immunity that was previously achieved through vaccination. To regain immunity to vaccine-preventable diseases, including measles, mumps, hepatitis, and diphtheria, patients need to be revaccinated following BMT.
Recent statistics from the National Cancer Institute estimate that 25% of adults with acute myeloid leukemia (AML) are expected to survive for ≥3 years. Depending on other prognostic factors, such as duration of first remission, age, performance status, cytogenetics, and prior hematopoietic stem cell transplant, the overall survival of patients with relapsed/refractory disease at 5 years was
Prescribing of Low-Molecular-Weight Heparin and Warfarin in Patients with Acute Venous Thromboembolism and Active Cancer
John Bossaer, PharmD, BCPS, Emily Flores, PharmD, BCACP, Brian Odle, PharmD, Somi Rikhye, MD, MPH, David W Stewart, PharmD, BCPS
Malignancy is a significant risk factor for venous thromboembolism (VTE), conferring a 4- to 7-fold increased risk in patients with cancer
It is important that patients treated with chemotherapy be educated about what to expect from their regimen and the correct use of supportive care medications at home.
Increased Incidence of Recurrent Venous Thromboembolism in Patients with Cancer Receiving Bevacizumab
Jonathan E. Dowell, MD, Sarah M. Gressett Ussery, PharmD, BCOP, Kevin C. Kelly, PharmD, BCPS, Sachin R. Shah, PharmD, BCOP, FCCP, Tanis L. Welch, PharmD
Angiogenesis, the development of new blood vessels from preexisting vessels, is considered to be one of the central “hallmarks” in most malignancies.
Page 3 of 5
Results 21 - 30 of 44
Results 21 - 30 of 44